Switch to:
Also traded in: Germany, Mexico, Spain, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
GIKLY's Cash-to-Debt is ranked higher than
89% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. GIKLY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GIKLY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.25 Max: No Debt
Current: No Debt
Equity-to-Asset 0.33
GIKLY's Equity-to-Asset is ranked lower than
83% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GIKLY: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
GIKLY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.33 Max: 0.37
Current: 0.33
0.28
0.37
Interest Coverage 3.89
GIKLY's Interest Coverage is ranked lower than
92% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GIKLY: 3.89 )
Ranked among companies with meaningful Interest Coverage only.
GIKLY' s Interest Coverage Range Over the Past 10 Years
Min: 1.56  Med: 4.15 Max: 18.28
Current: 3.89
1.56
18.28
Piotroski F-Score: 7
Altman Z-Score: 2.09
Beneish M-Score: -1.90
WACC vs ROIC
5.02%
13.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 23.13
GIKLY's Operating Margin % is ranked higher than
89% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. GIKLY: 23.13 )
Ranked among companies with meaningful Operating Margin % only.
GIKLY' s Operating Margin % Range Over the Past 10 Years
Min: 15.53  Med: 24.74 Max: 26.85
Current: 23.13
15.53
26.85
Net Margin % 13.35
GIKLY's Net Margin % is ranked higher than
85% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. GIKLY: 13.35 )
Ranked among companies with meaningful Net Margin % only.
GIKLY' s Net Margin % Range Over the Past 10 Years
Min: 2.8  Med: 13.04 Max: 16.2
Current: 13.35
2.8
16.2
ROE % 15.60
GIKLY's ROE % is ranked higher than
91% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. GIKLY: 15.60 )
Ranked among companies with meaningful ROE % only.
GIKLY' s ROE % Range Over the Past 10 Years
Min: 4.27  Med: 18.11 Max: 28.28
Current: 15.6
4.27
28.28
ROA % 5.52
GIKLY's ROA % is ranked higher than
86% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. GIKLY: 5.52 )
Ranked among companies with meaningful ROA % only.
GIKLY' s ROA % Range Over the Past 10 Years
Min: 1.34  Med: 6.27 Max: 11.48
Current: 5.52
1.34
11.48
ROC (Joel Greenblatt) % 32.16
GIKLY's ROC (Joel Greenblatt) % is ranked higher than
87% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. GIKLY: 32.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GIKLY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.67  Med: 30.3 Max: 41.3
Current: 32.16
17.67
41.3
3-Year Revenue Growth Rate 13.70
GIKLY's 3-Year Revenue Growth Rate is ranked higher than
66% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. GIKLY: 13.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GIKLY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 7.7  Med: 14.6 Max: 28.2
Current: 13.7
7.7
28.2
3-Year EBITDA Growth Rate 10.40
GIKLY's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. GIKLY: 10.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GIKLY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 8.2  Med: 28.9 Max: 38.4
Current: 10.4
8.2
38.4
3-Year EPS without NRI Growth Rate 16.20
GIKLY's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. GIKLY: 16.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GIKLY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -31.6  Med: 27.7 Max: 105.1
Current: 16.2
-31.6
105.1
GuruFocus has detected 4 Warning Signs with Grifols SA $GIKLY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GIKLY's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412 
Compare:NAS:BMRN, OTCPK:GMXAY, OTCPK:UCBJY, OTCPK:NVZMY, NAS:JAZZ, NAS:INCY, NAS:ALKS, NAS:ALXN, NAS:SGEN, OTCPK:ALIOY, NAS:TSRO, NAS:ALNY, NAS:EXEL, NAS:IONS, NAS:BIVV, NAS:UTHR, NAS:KITE, NAS:ARIA, NAS:BLUE, NAS:TECH » details
Traded in other countries:G0FB.Germany, GRFPN.Mexico, GRF.P.Spain, 0RDU.UK, GRFS.USA,
Headquarter Location:Spain
Grifols SA is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. It operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials.

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 90% of sales in 2013. Grifols also has smaller segments including diagnostics, hospital supplies, and raw materials, but diagnostics grew to almost 20% of revenue in 2014 with the acquisition of Novartis' diagnostics unit.

Ratios

vs
industry
vs
history
PE Ratio 31.22
GIKLY's PE Ratio is ranked higher than
50% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 31.55 vs. GIKLY: 31.22 )
Ranked among companies with meaningful PE Ratio only.
GIKLY' s PE Ratio Range Over the Past 10 Years
Min: 21.8  Med: 33.05 Max: 96.2
Current: 31.22
21.8
96.2
Forward PE Ratio 24.63
GIKLY's Forward PE Ratio is ranked lower than
57% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 22.68 vs. GIKLY: 24.63 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 31.22
GIKLY's PE Ratio without NRI is ranked higher than
51% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 31.76 vs. GIKLY: 31.22 )
Ranked among companies with meaningful PE Ratio without NRI only.
GIKLY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 21.72  Med: 31.63 Max: 97.1
Current: 31.22
21.72
97.1
Price-to-Owner-Earnings 34.83
GIKLY's Price-to-Owner-Earnings is ranked higher than
51% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.51 vs. GIKLY: 34.83 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GIKLY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.11  Med: 32.5 Max: 47.23
Current: 34.83
18.11
47.23
PB Ratio 4.65
GIKLY's PB Ratio is ranked lower than
57% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. GIKLY: 4.65 )
Ranked among companies with meaningful PB Ratio only.
GIKLY' s PB Ratio Range Over the Past 10 Years
Min: 2.32  Med: 4.22 Max: 6.76
Current: 4.65
2.32
6.76
PS Ratio 4.21
GIKLY's PS Ratio is ranked higher than
74% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. GIKLY: 4.21 )
Ranked among companies with meaningful PS Ratio only.
GIKLY' s PS Ratio Range Over the Past 10 Years
Min: 1.95  Med: 3.57 Max: 12.85
Current: 4.21
1.95
12.85
Price-to-Free-Cash-Flow 50.81
GIKLY's Price-to-Free-Cash-Flow is ranked lower than
74% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 28.96 vs. GIKLY: 50.81 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GIKLY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 15.6  Med: 31.04 Max: 121.38
Current: 50.81
15.6
121.38
Price-to-Operating-Cash-Flow 27.28
GIKLY's Price-to-Operating-Cash-Flow is ranked lower than
53% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 25.50 vs. GIKLY: 27.28 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GIKLY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.02  Med: 19.04 Max: 169.33
Current: 27.28
11.02
169.33
EV-to-EBIT 16.01
GIKLY's EV-to-EBIT is ranked higher than
62% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. GIKLY: 16.01 )
Ranked among companies with meaningful EV-to-EBIT only.
GIKLY' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.7  Med: 19.8 Max: 45.1
Current: 16.01
12.7
45.1
EV-to-EBITDA 13.20
GIKLY's EV-to-EBITDA is ranked higher than
63% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 18.63 vs. GIKLY: 13.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
GIKLY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.3  Med: 16.05 Max: 37.1
Current: 13.2
10.3
37.1
PEG Ratio 1.51
GIKLY's PEG Ratio is ranked higher than
57% of the 103 Companies
in the Global Biotechnology industry.

( Industry Median: 2.15 vs. GIKLY: 1.51 )
Ranked among companies with meaningful PEG Ratio only.
GIKLY' s PEG Ratio Range Over the Past 10 Years
Min: 0.55  Med: 0.97 Max: 1.72
Current: 1.51
0.55
1.72
Current Ratio 3.12
GIKLY's Current Ratio is ranked lower than
59% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. GIKLY: 3.12 )
Ranked among companies with meaningful Current Ratio only.
GIKLY' s Current Ratio Range Over the Past 10 Years
Min: 2.19  Med: 2.99 Max: 3.31
Current: 3.12
2.19
3.31
Quick Ratio 1.34
GIKLY's Quick Ratio is ranked lower than
79% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. GIKLY: 1.34 )
Ranked among companies with meaningful Quick Ratio only.
GIKLY' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.46 Max: 1.88
Current: 1.34
1.15
1.88
Days Inventory 263.77
GIKLY's Days Inventory is ranked lower than
82% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. GIKLY: 263.77 )
Ranked among companies with meaningful Days Inventory only.
GIKLY' s Days Inventory Range Over the Past 10 Years
Min: 235.92  Med: 290.24 Max: 909.7
Current: 263.77
235.92
909.7
Days Sales Outstanding 42.65
GIKLY's Days Sales Outstanding is ranked higher than
69% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. GIKLY: 42.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
GIKLY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.62  Med: 68.57 Max: 90.49
Current: 42.65
33.62
90.49
Days Payable 77.46
GIKLY's Days Payable is ranked higher than
62% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. GIKLY: 77.46 )
Ranked among companies with meaningful Days Payable only.
GIKLY' s Days Payable Range Over the Past 10 Years
Min: 64.56  Med: 101.37 Max: 256.52
Current: 77.46
64.56
256.52

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.19
GIKLY's Dividend Yield % is ranked higher than
64% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. GIKLY: 1.19 )
Ranked among companies with meaningful Dividend Yield % only.
GIKLY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.38  Med: 1.24 Max: 1.79
Current: 1.19
0.38
1.79
Dividend Payout Ratio 0.39
GIKLY's Dividend Payout Ratio is ranked lower than
59% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.39 vs. GIKLY: 0.39 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GIKLY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.26 Max: 0.56
Current: 0.39
0.14
0.56
3-Year Dividend Growth Rate 46.30
GIKLY's 3-Year Dividend Growth Rate is ranked higher than
91% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. GIKLY: 46.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
GIKLY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 46.3
Current: 46.3
0
46.3
Forward Dividend Yield % 1.03
GIKLY's Forward Dividend Yield % is ranked higher than
67% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. GIKLY: 1.03 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.19
GIKLY's 5-Year Yield-on-Cost % is ranked higher than
53% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.57 vs. GIKLY: 1.19 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GIKLY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.38  Med: 1.24 Max: 1.79
Current: 1.19
0.38
1.79
3-Year Average Share Buyback Ratio 0.20
GIKLY's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. GIKLY: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GIKLY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -46.1  Med: -15.3 Max: 20.3
Current: 0.2
-46.1
20.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.17
GIKLY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
64% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 3.46 vs. GIKLY: 2.17 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GIKLY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.62  Med: 2.25 Max: 2.78
Current: 2.17
1.62
2.78
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.10
GIKLY's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
65% of the 26 Companies
in the Global Biotechnology industry.

( Industry Median: 1.49 vs. GIKLY: 1.10 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.18
GIKLY's Price-to-Median-PS-Value is ranked lower than
65% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. GIKLY: 1.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GIKLY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 0.99 Max: 3.27
Current: 1.18
0.59
3.27
Price-to-Peter-Lynch-Fair-Value 1.70
GIKLY's Price-to-Peter-Lynch-Fair-Value is ranked higher than
53% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 1.85 vs. GIKLY: 1.70 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GIKLY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.95  Med: 1.04 Max: 1.72
Current: 1.7
0.95
1.72
Earnings Yield (Greenblatt) % 6.25
GIKLY's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. GIKLY: 6.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GIKLY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 5 Max: 7.9
Current: 6.25
2.2
7.9
Forward Rate of Return (Yacktman) % 20.44
GIKLY's Forward Rate of Return (Yacktman) % is ranked higher than
60% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. GIKLY: 20.44 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GIKLY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 20.4  Med: 28.5 Max: 45.7
Current: 20.44
20.4
45.7

More Statistics

Revenue (TTM) (Mil) $4,531.65
EPS (TTM) $ 0.45
Beta0.44
Short Percentage of Float0.00%
52-Week Range $8.90 - 14.83
Shares Outstanding (Mil)1,366.51 (ADR)

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 4,860 5,148
EPS ($) 0.61 0.69
EPS without NRI ($) 0.61 0.69
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.80%
Dividends per Share ($) 0.23 0.26
» More Articles for GIKLY

Headlines

Articles On GuruFocus.com
Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for Jun 22 2017 
Grifols and Beckman Coulter Enter into an Exclusive Distribution Agreement Jun 12 2017 
Investigational New Drug Application is Now Effective for Babesia Screening in Blood Donations Using May 09 2017 
Grifols Strengthens Position as Global Provider of Diagnostic Testing Solutions with Five-Year Exten Apr 24 2017 
Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Apr 17 2017 
Grifols 2016 Annual Report on Form 20-F filed with the SEC on April 4, 2017 Apr 04 2017 
John Paulson's Largest 3rd Quarter Trades Dec 01 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
Gold-Focused Guru John Paulson Reports First Quarter Holdings May 22 2014 
Is Grifols Being Overlooked? Mar 19 2014 

More From Other Websites
Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for... Jun 22 2017
When 'New' Means A Stock Hasn't Led The Market In A While Jun 21 2017
Should Value Investors Consider Grifols (GRFS) Stock Right Now? Jun 16 2017
Grifols and Beckman Coulter Enter into an Exclusive Distribution Agreement Jun 12 2017
Grifols SA : GIKLY-US: Dividend Analysis : June 01st, 2017 (record date) : By the numbers : June 1,... Jun 01 2017
Investigational New Drug Application is Now Effective for Babesia Screening in Blood Donations Using... May 09 2017
Grifols Strengthens Position as Global Provider of Diagnostic Testing Solutions with Five-Year... Apr 24 2017
Can young blood pump new life into treatments for diseases of aging? Apr 19 2017
Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of... Apr 17 2017
Grifols World Wide Operations USA, Inc. -- Moody's assigns B2 to Grifols' new EUR1 billion notes Apr 12 2017
Grifols 2016 Annual Report on Form 20-F filed with the SEC on April 4, 2017 Apr 04 2017
New Strong Buy Stocks for March 30th Mar 30 2017
Is Grifols a Great Stock for Value Investors? Mar 17 2017
Grifols SA :GIKLY-US: Earnings Analysis: 2016 By the Numbers : March 6, 2017 Mar 06 2017
Grifols SA : Good buy or value trap? Feb 24 2017
Grifols closes the acquisition of Hologic's share of NAT donor screening unit for USD 1,850 million Jan 31 2017
Grifols World Wide Operations Ltd. -- Moody's assigns Ba2 to Grifols' new term loans and revolver;... Jan 13 2017
Grifols S.A. -- Moody's downgrades Grifols' CFR to Ba3 from Ba2, stable outlook Dec 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}